Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Urothelial Bladder Carcinoma × Genitourinary × Clear all

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2666 Carcinoma, Renal Cell 777 Urinary Bladder Neoplasms 633 Kidney Neoplasms 397 Breast Neoplasms 358 Neoplasms 353 Neoplasm Metastasis 206 Carcinoma, Non-Small-Cell Lung 199 Lung Neoplasms 192 Ovarian Neoplasms 182 Colorectal Neoplasms 178 Carcinoma, Transitional Cell 166 Melanoma 165 Testicular Neoplasms 146 Pancreatic Neoplasms 121 Sarcoma 116 Head and Neck Neoplasms 107 Wilms Tumor 104 Colonic Neoplasms 103 Uterine Cervical Neoplasms 102 Neuroblastoma 80 Stomach Neoplasms 78 Multiple Myeloma 77 Lymphoma, Non-Hodgkin 76 Lymphoma 71 Carcinoma, Ovarian Epithelial 70 Esophageal Neoplasms 68 Carcinoma, Hepatocellular 67 Squamous Cell Carcinoma of Head and Neck 66 Recurrence 66

Interventions

pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02736266 2023-07-18

PURE-01

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡